Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: Sign informed consent Age: ≥18 years Expected survival > or = 3months Has documented locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease. Agree to provide a tumor sample Has at least one measurable lesion based on RECIST 1.1 Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1 Exclusion Criteria: Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration Mixed small-cell lung cancer (SCLC) and NSCLC histology Subjects with history of severe heart disease Active autoimmune diseases and inflammatory diseases Other malignant tumors were diagnosed within 5 years Subjects with poorly controlled hypertension Subjects have Grade 3 lung disease or a history of interstitial lung disease Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring therapeutic intervention within the previous 6 months before screening Symptoms of active central nervous system metastasis. Subjects who have a history of allergies to recombinant humanized antibodies or human mouse chimeric antibodies or any of the components of BL-B01D1 Subjects have a history of autologous or allogeneic stem cell transplantation Known HIV, active tuberculosis, active Hepatitis B virus infection or active Hepatitis C virus infection Subjects with active infections requiring systemic treatment Participated in another clinical trial within 4 weeks prior to participating in the study Other conditions that the investigator believes that it is not suitable for participating in this clinical trial